Issue release date: 12.11.2024
2Istanbul Medipol University, School of Medicine, Department of Medical Pharmacology, Istanbul, Turkey
3Cumhuriyet University, School of Medicine, Department of Radiation Oncology, Sivas, Turkey
4Namik Kemal University, Faculty of Arts and Sciences, Department of Molecular Biology and Genetics, Tekirdag, Turkey
5Istanbul Esenyurt University, Esencan Hospital, Neurosurgery Clinic, Istanbul, Turkey DOI : 10.5137/1019-5149.JTN.22467-18.3 AIM: To systematically investigate the role of artificial small interfering RNA (siRNA) molecules in glioblastoma treatment and to give a detailed overview of the literature concerning studies performed in this field worldwide in the last 31 years.
MATERIAL and METHODS: Articles about clinical trials conducted between December 1, 1949 and November 8, 2017, were identified from the Cochrane Collaboration, the Cochrane Library, Ovid MEDLINE, ProQuest, the National Library of Medicine, and PubMed electronic databases, using the terms âpost transcriptional gene silencing,â âsmall interfering RNA,â âsiRNA,â and âglioblastoma,â either individually or combined (âORâ and âANDâ), without language and country restrictions. Articles that met the examination criteria were included in the study. After descriptive statistical evaluation, the results were reported in frequency (%).
RESULTS: After scanning 2.752 articles, five articles were found that met the research criteria. Examination of full texts of the five identified articles provided no sufficient evidence for research conducted with regard to the use of gene silencing via siRNAs in glioblastoma treatment.
CONCLUSION: To be able to evaluate the clinical use of siRNAs, there is an urgent need for in vivo studies and for trials with randomized, controlled, and clinical designs that provide long-term functional outcomes.
Keywords : Brain tumor, Glioblastoma, Posttranscriptional gene silencing, siRNA vector